Your activity: 104 p.v.
your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

COVID-19 vaccine schedule for adults, adolescents, and children ≥5 years old with moderately to severely immunocompromising conditions

COVID-19 vaccine schedule for adults, adolescents, and children ≥5 years old with moderately to severely immunocompromising conditions
Individuals with moderately to severely immunocompromising conditions have a higher risk of suboptimal response to COVID-19 vaccination. Thus, an additional primary series dose, is a strategy to improve vaccine effectiveness in this population. Such patients are also eligible for pre-exposure prophylaxis. Refer to other UpToDate content for examples of moderately to severely immunocompromising conditions that warrant this adjusted vaccination schedule.

* If possible, the same vaccine formulation should used to complete the primary series. If the original vaccine is not available or if the patient has developed a contraindication to that vaccine, a different, age-appropriate COVID-19 vaccine can be used to complete the primary series; in such cases, the new dose is given at least 4 weeks after the last one.

¶ If the patient received monovalent booster doses in addition to the primary series, a single booster dose of a bivalent vaccine is still recommended, at least 2 months following the most recent monovalent vaccine dose.

For individuals 18 years or older who have received a primary vaccine series but no prior booster dose and are unable or unwilling to receive an mRNA vaccine, a single dose of NVX-CoV2373 can be used as a booster dose at least 6 months after the last primary series dose.
Graphic 138339 Version 8.0